Although the clinical guidelines for nonalcoholic fatty liver disease (NAFLD) therapy recommended hepato-protection and exercise to reduce body weight, no established medication exists for NAFLD treatment. Thus, the effect of a candidate substance, dansameum (DSE), using an in vitro and NAFLD mouse model (that is, apolipoprotein E-Knockout mice), were investigated. The molecular pathways for lipogenesis and inflammation were evaluated using Nile staining, Western blotting, reverse transcription-polymerase chain reaction, and immunohistochemistry. It was shown that DSE significantly ameliorated the production of lipogenesis-related factors, including liver X receptor-α, peroxisome proliferator-activated receptor-γ, sterol regulatory element binding protein-1, fatty acid synthase, acetyl-CoA carboxylase 1, and CD36. In addition, DSE significantly reduced the production of inflammation factors, including interleukin-1β, interleukin-6, and nuclear factor kappa B. Furthermore, DSE significantly reduced the phosphorylation of c-Jun amino terminal kinase. Taken together, this suggests that DSE may be a functional food candidate for regulating NAFLD, based on its effects.

中文翻译：

---

丹参可在体内和体外调节肝脏脂肪生成和炎症。

尽管非酒精性脂肪肝疾病（NAFLD）治疗的临床指南建议通过保肝和运动来减轻体重，但尚无用于NAFLD治疗的既定药物。因此，使用体外和NAFLD小鼠模型（即载脂蛋白E基因敲除小鼠）研究了候选物质dansameum（DSE）的作用。使用尼罗河染色，蛋白质印迹，逆转录聚合酶链反应和免疫组织化学评估脂肪形成和炎症的分子途径。结果表明DSE显着改善了与脂肪生成有关的因子的产生，包括肝X受体α，过氧化物酶体增殖物激活的受体γ，固醇调节元件结合蛋白-1，脂肪酸合酶，乙酰辅酶A羧化酶1和CD36。 。此外，DSE显着降低了炎症因子（包括白介素-1β，白介素-6和核因子κB）的产生。此外，DSE显着降低了c-Jun氨基末端激酶的磷酸化。两者合计，这表明DSE基于其影响可能是调节NAFLD的功能性候选食品。